Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort

What is it about?

In this population based large cohort study including 10114 Korean type 2 diabetes patients, primary outcome of composite of myocardial infarction, stroke, coronary revascularization and cardiac death was significantly lower in fenofibrate users by 24% and total death was lower by 56%. This benefit persisted regardless of statin use or serum lipid profile in fenofibrate group.

Featured Image